Live Breaking News & Updates on சிர்தெக்ஷ ப்டி லிமிடெட்
Stay updated with breaking news from சிர்தெக்ஷ ப்டி லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CLEVELAND, Aug. 5, 2021 /PRNewswire/ MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for MAA voxel-based SPECT/CT ....
Press release content from PR Newswire. The AP news staff was not involved in its creation. DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient May 10, 2021 GMT Sirtex DOORwaY-90 Study Logo First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres® Y-90 resin microspheres taking place in 15 sites across the U.S. WOBURN, Mass., May 10, 2021 /PRNewswire/ Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the first patient has been enrolled in DOORwaY-90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma (HCC). ....
Share this article Share this article WOBURN, Mass., April 19, 2021 /PRNewswire/ Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, and BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private company developing groundbreaking therapies in endovascular embolization, announced that the first patient has been enrolled in the LAVA Study to evaluate the safety and effectiveness of the BlackSwan Lava™ liquid embolic system (LES) for the embolic treatment of arterial hemorrhage in the peripheral vasculature. The LAVA Study, which stands for Liquid Embolization of Arterial Hemorrhages in Peripheral Vasculature, is a prospective, multicenter single-arm study of 113 subjects at 20 investigational sites in the U.S. The first subject has been enrolled at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, where a clinical team successfully treated a patient with a bleeding hypervascular tum ....
Sirtex Medical receives positive recommendation from National Institute for Health and Care Excellence (NICE) for selective internal radiation therapy (SIRT) using SIR-Spheres WOBURN, Mass., Feb. 26, 2021 /PRNewswire/ Sirtex Medical US Holdings, Inc. ( Sirtex ), a leading manufacturer of targeted cancer therapies, received positive guidance from the National Institute for Health and Care Excellence (NICE) regarding the use of selection internal radiation therapy (SIRT) with SIR-Spheres Y-90 microspheres for the treatment of adults with unresectable advanced hepatocellular carcinoma (HCC). NICE recommends the use of SIRT using SIR-Spheres in England and Wales as a fully funded and reimbursed option for adult patients with HCC, on the conditions that it is used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and that the company provides SIR-Spheres according to the commercial arrangement. ....
Sirtex Medical announces collaboration update with OncoSec Medical News provided by Share this article TAVO™ for the treatment of advanced melanoma WOBURN, Mass., Jan. 19, 2021 /PRNewswire/ Sirtex Medical US Holdings, Inc. ( Sirtex ), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec s lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system. The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO™ and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec. ....